| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 396.3 | 345.3 |
| Profit before tax | 30.8 | -69.5 |
| Net income | 15.6 | -31.6 |
| EPS (diluted, $ a share) | $0.07 | $-9.67 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +14.8% |
|---|---|
| Operating margin | 5.8% |
10-Q filed with the SEC, NASDAQ: PIII. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
P3 Health Partners Inc.: key numbers
- Share price
- $2.41Close, Nov 16
- Sector
- Industrial Applications and Services
- Industry
- Services-Health ServicesSIC 8000
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from P3 Health Partners Inc.
All →P3 Health Partners Earnings Call: Key Takeaways
P3 Health Partners achieved its third consecutive profitable quarter, raising full-year Adjusted EBITDA guidance midpoint to $100 million while highlighting a $200 million value creation pipeline.
- Call
- Nov 9, 2026, 4:30 PM ET
P3 Health Partners Financial Results
P3 Health Partners reported Q3 2026 financial results with revenue of $396 million, up 15% year-over-year, and net income of $30.8 million. The company raised its full-year 2026 Adjusted EBITDA guidance midpoint to $100 million based on strong year-to-date performance and improved network economics.
- Term
- Q3 2026
“This was another strong quarter for P3. The foundation we have built over the past two years is showing up both in the care our patients receive and in the consistency of our results. We carry real momentum into 2027, as evidenced by our medical cost trend, and I am excited about what lies ahead for our patients, our providers, and our partners.”
Dr. Aric Coffman, CEO of P3